Advice
Following a resubmission
ivabradine (Procoralan) is accepted for restricted use within NHS Scotland for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm for whom heart rate control is desirable and who have a contra-indication or intolerance for beta-blockers and rate-limiting calcium-channel blockers.
Non-inferiority of ivabradine versus a beta blocker and a calcium-channel blocker was shown in two controlled trials. Long-term protection against cardiovascular events, however, has not been demonstrated
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- Ivabradine (Procoralan®)
- SMC ID:
- 319/06
- Indication:
- Chronic stable angina
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 12 March 2007